Therefore, the present study aims to determine whether miR-92d-3p can target complement C3 to modulate the activity of the C3/HMGB1/TGF-β1 pathway, inhibit immune inflammatory response and EMT associated with DN, and prevent or slow down the progress of DN. The gene discussed is TGFB1; the disease is liver dysplastic nodule.